Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent

PURPOSE: Ataxia telangiectasia mutated (ATM) is a key mediator of the DNA damage response, and several ATM inhibitors (ATMi) are currently undergoing early phase clinical trials for the treatment of cancer. A radiolabelled ATMi to determine drug pharmacokinetics could assist patient selection in a m...

Descripción completa

Detalles Bibliográficos
Autores principales: Fraser, Claudia Rose, Ajenjo, Javier, Veal, Mathew, Dias, Gemma Marie, Chan, Chung, O’Neill, Edward, Destro, Gianluca, Lau, Doreen, Pacelli, Anna, Gouverneur, Veronique, Hueting, Rebekka, Cornelissen, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375819/
https://www.ncbi.nlm.nih.gov/pubmed/35962885
http://dx.doi.org/10.1186/s13550-022-00920-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375819/
https://www.ncbi.nlm.nih.gov/pubmed/35962885
http://dx.doi.org/10.1186/s13550-022-00920-z

Ejemplares similares